BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8618446)

  • 1. Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia.
    Kaspers GJ; Veerman AJ; Van Wering ER; Van Der Linden-Schrever BE; Van Zantwijk CH; Van Der Does-Van Den Berg A; Pieters R
    Leukemia; 1996 Apr; 10(4):675-81. PubMed ID: 8618446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of cross-resistance between prednisolone and methotrexate in childhood acute lymphoblastic leukemia? A preliminary analysis.
    Hegge IR; Kaspers GJ; Rots MG; Jansen G; Pieters R; Veerman AJ
    Adv Exp Med Biol; 1999; 457():551-5. PubMed ID: 10500833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.
    Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Van Der Does-Van Den Berg A; Veerman AJ
    Blood; 1998 Jul; 92(1):259-66. PubMed ID: 9639525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peanut agglutinin, a marker for T-cell acute lymphoblastic leukemia with a good prognosis.
    Veerman AJ; Hogeman PH; Huismans DR; Van Zantwijk CH; Bezemer PD
    Cancer Res; 1985 Apr; 45(4):1890-3. PubMed ID: 3872169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
    Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
    J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
    Morishita N; Tsukahara H; Chayama K; Ishida T; Washio K; Miyamura T; Yamashita N; Oda M; Morishima T
    Pediatr Blood Cancer; 2012 Jul; 59(1):83-9. PubMed ID: 22183914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro resistance of leukaemic blasts to prednisolone in bcr-abl positive childhood acute lymphoblastic leukaemia.
    Gupta M; Kumar A; Dabadghao S
    Indian J Med Res; 2002 Dec; 116():268-72. PubMed ID: 12807155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
    Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
    Falletta JM; Shuster JJ; Crist WM; Pullen DJ; Borowitz MJ; Wharam M; Patterson R; Foreman E; Vietti TJ
    Leukemia; 1992 Jun; 6(6):541-6. PubMed ID: 1602793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
    Styczynski J; Koltan A; Wysocki M
    Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
    Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
    Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.